Consistent with our findings, other investigators also found that decreased ARID1A expression is significantly associated with a higher grade of breast cancer [22], as well as a higher FIGO stage in ovarian clear cell carcinoma [21]. This evidence concerns the gene ARID1A and ovarian clear cell cancer.